Biopharmaceutical company TikoMed has announced two new appointments to its Board of Directors as the company focuses on its ILB drug programme. TikoMed has appointed Tara Heitner and Pete Zorn to its Board of Directors. Tara Heitner has more than 15 years of experience in the biopharmaceutical industry and has been involved in the development […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!